These data highlight the importance of monitoring utrophin and embryonic myosin levels in preclinical evaluation of utrophin modulators and provide translational support for use of developmental myosin as a disease biomarker in DMD clinical trials. This evidence concerns the gene UTRN and Duchenne muscular dystrophy.